Vera Therapeutics, Inc. · NASDAQ:VERA

Vera Therapeutics — Investor Presentation (October 2026)

28 slides from Vera Therapeutics's investor presentation, October 2026

  1. Slide 1: Corporate Presentation

    Corporate Presentation October 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation

  2. Slide 2: Forward-looking statements

    Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements in this presentation that are not statements of historical fact are "forward-looking statements" within the meaning of the

  3. Slide 3: Disclaimer: Indication and Important Safety Information

    Disclaimer Indication: TRUTAKNA™ (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established wheth

  4. Slide 4: Vera is a San Francisco-based biotechnology company

    • VERA (Nasdaq) is a San Francisco-based biotechnology company with world-class development and commercialization leadership • First commercial product: TRUTAKNA™ (atacicept-vymj), a first-in-class BAFF and APRIL inhibitor that could transform treatment of autoimmune disease • FDA granted accelerate

  5. Slide 5: Vera pipeline

    Vera pipeline Research & Discovery Preclinical Clinical Marketed IgAN TRUTAKNA pMN, FSGS, MCD Phase 2 Potential future autoimmune indications MAU868 BK virus Phase 2 Potential future VT-109 autoimmune indications Vera holds worldwide, exclusive rights to develop and commercialize TRUTAKNA, VT-109, a

  6. Slide 6: Management team: Successful clinical and commercial track record

    Management team: Successful clinical and commercial track record Marshall Fordyce, MD Nancy Boman, MD, PhD Robert Brenner, MD Lauren Frenz, MBA Founder and CEO Chief Regulatory Officer Chief Medical Officer Chief Business Officer Sean Grant, MBA David Johnson, MBA Matt Skelton Jane Wright-Mitchell C

  7. Slide 7: Strong financial position

    Strong financial position ~$499M ~72.1M Cash, cash equivalents, Shares outstanding (as of 7.29.26) and marketable securities (as of 6.30.26) Additional $425M non-dilutive capital available through Oxford Facility, subject to satisfaction of certain conditions 7 © 2026 Vera Therapeutics, Inc. Corpora

  8. Slide 8: Inhibition of immune complex formation in IgAN may avoid end-stage kidney disease

    Inhibition of immune complex formation in IgAN may offer the potential to avoid end-stage kidney disease during a patient’s lifetime 80 71 5-Year % Mortality in US1,2 60 59 ESKD 5-year mortality comparable to cancer 40 35 20 8 0 Lung ESKD Colorectal Breast Cancer Cancer Cancer ESKD, end stage kidney

  9. Slide 9: Atacicept: Rationally designed fusion protein conceived in the era of modern biotechnology

    Atacicept: Rationally designed fusion protein conceived in the era of modern biotechnology IgAN is a disease of B cell origin with kidney pathology BAFF TACI Gd-IgA1 Hematuria Proteinuria eGFR stabilization, B cell reduction resolution reduction kidney protection APRIL TACI receptor Atacicept domain

  10. Slide 10: ORIGIN Phase 2b long-term results appear consistent with disease modification

    ORIGIN Phase 2b long-term results appear consistent with disease modification Reduction in Gd-IgA1 Resolution of hematuria 0 0 Mean ± SE % Change from in % Participants (95% CI) -15 -20 Change from Baseline Baseline in Gd-IgA1 -30 -40 -45 -60 -60 -80 -75% -66% -75 -100 0 12 24 36 48 60 72 96 0 12 24

  11. Slide 11: ORIGIN trial design

    ORIGIN 3 trial design Multinational, randomized, placebo-controlled trial of TRUTAKNA, self-administered at home via weekly 1-mL SC injection Double-blind treatment* Open-label extension Placebo TRUTAKNA 150 mg SC QW TRUTAKNA 150 mg SC QW Week 0 36 52 104 156 1° Endpoint met Final analysis: 2° Endpo

  12. Slide 12: Primary endpoint: UPCR reduction

    Primary endpoint: UPCR reduction Δ 42% 95% CI 29, 52 10 10 p<0.0001 Mean (95% CI) % Change from Baseline 0 0 -10 -10 -20 -20 -7% -30 -30 95% CI -19, 8 -40 -40 -50 -50 -60 -60 -46% 0 12 24 36 95% CI -53, -38 n= Week Placebo 97 96 97 95 TRUTAKNA Placebo TRUTAKNA 106 104 104 103 n=103 n=95 Interim Anal

  13. Slide 13: TRUTAKNA was generally well tolerated in ORIGIN interim analysis

    TRUTAKNA was generally well tolerated in ORIGIN 3 interim analysis TRUTAKNA Placebo Participants, % n=214 n=214 Most common adverse events (≥5%) • Most adverse events were mild or moderate in Infections 32 28 severity and resolved without treatment interruption or discontinuation Upper respiratory t

  14. Slide 14: Vera Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis

    Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy • Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027 • Pending positive eGFR analysis, plans to submit

  15. Slide 15: Final efficacy analysis: Patient disposition

    Final efficacy analysis: Patient disposition 750 screened 319 failed screening 431 randomized 3 randomized but not dosed1 428 randomized and dosed Full analysis set and 214 TRUTAKNA 214 placebo safety analysis set 15 discontinued treatment 45 discontinued treatment 8 patient withdrawals 22 adverse e

  16. Slide 16: Baseline demographics and characteristics

    Baseline demographics and characteristics TRUTAKNA Placebo Total n=214 n=214 n=428 Age, years, median (range) 41 (18, 74) 41 (18, 70) 41 (18, 74) Male sex, n (%) 122 (57) 132 (62) 254 (59) Race, n (%) Asian 117 (55) 114 (53) 231 (54) White 94 (44) 95 (44) 189 (44) Other 3 (1) 5 (2) 8 (2) Region, n (

  17. Slide 17: TRUTAKNA treatment resulted in a physiologic rate of eGFR loss

    TRUTAKNA treatment resulted in a physiologic rate of eGFR loss vs pathologic rate of eGFR loss with placebo 2 Mean change from baseline1 Annualized at 52 weeks at 104 weeks eGFR slope2 Mean (95% CI) eGFR change from baseline, 0 -2 Placebo- adjusted Δ5.6 Δ11.1 Δ5.0 (3.7, 7.5) (7.7, 14.4) (3.6, 6.5) d

  18. Slide 18: TRUTAKNA eGFR benefit observed across all prespecified subgroups

    TRUTAKNA eGFR benefit observed across all prespecified subgroups Mean (95% CI) placebo-adjusted Mean (95% CI) placebo-adjusted n (%) eGFR change at 52 weeks, mL/min/1.73m2 annualized eGFR slope, mL/min/1.73m2/yr Overall 428 5.6 (3.7, 7.5) 5.0 (3.6, 6.5) <40 189 (44) 6.6 (3.6, 9.6) 6.6 (4.2, 9.0) Age

  19. Slide 19: TRUTAKNA achieved 76% risk reduction in the composite kidney disease progression endpoint

    TRUTAKNA achieved 76% risk reduction in the composite kidney disease progression endpoint TRUTAKNA Placebo Composite kidney disease progression through 104 weeks Hazard ratio Risk reduction 40 38 18% 0.24 76% (95% CI 0.12, 0.48) 30 p<0.0001 Participants, n A composite kidney disease progression even

  20. Slide 20: TRUTAKNA reduced UPCR, Gd-IgA1, and hematuria

    TRUTAKNA reduced UPCR, Gd-IgA1, and hematuria through 104 weeks UPCR reduction1 Gd-IgA1 reduction2 Hematuria resolution3 25 0 30 Change from baseline in % participants Mean (95% CI) % change from baseline Mean (95% CI) % change from baseline 15 Placebo -20 0 with hematuria (95% CI) 0 -40 -15 -25 -30

  21. Slide 21: TRUTAKNA was well tolerated with a favorable safety profile

    TRUTAKNA was well tolerated with a favorable safety profile, and generally comparable to placebo TRUTAKNA Placebo Participants, n (%) n=214 n=214 Adverse events 160 (75) 167 (78) • Most adverse events were mild or moderate in severity and resolved without treatment Serious adverse events1 15 (7) 33

  22. Slide 22: Atacicept in IgA Nephropathy: Phase 3 Trial Final Efficacy Analysis

    Atacicept in IgA Nephropathy: Phase 3 Trial Final Efficacy Analysis published in The New England Journal of Medicine Scan to visit NEJM.org Barratt J, et al. N Engl J Med 2026. doi/full/10.1056/NEJMoa2610103. 22 © 2026 Vera Therapeutics, Inc. Corporate Presentation

  23. Slide 23: Conclusions

    Conclusions • ORIGIN 3 demonstrates that TRUTAKNA has the potential for comprehensive disease modification in IgAN • TRUTAKNA treatment resulted in a physiologic rate of eGFR loss compared to a pathologic rate of eGFR loss with placebo • ORIGIN 3 met all prespecified endpoints, including placebo-adj

  24. Slide 24: Estimated IgAN epidemiology in 2032

    Estimated IgAN epidemiology in 2032 US IgAN Prevalence: ~0.04% of US Population (360.5M)1 + ~40K ~160K Low Risk (~24% of patients)2 + ~30K Moderate Risk (~20% of patients)2 ~90K High Risk (~56% of patients)2 Phase 3 population Phase 2 study ongoing BAFF & APRIL inhibition 24 © 2026 Vera Therapeutics

  25. Slide 25: IgAN market and TRUTAKNA have many hallmarks of an attractive commercial opportunity

    IgAN market and TRUTAKNA have many hallmarks of an attractive commercial opportunity IgAN Market TRUTAKNA • We believe the nephrology market is ripe for • Potentially differentiating product attributes disruption due to limited adoption of • Phase 2b eGFR data highly valued with approved therapies e

  26. Slide 26: Potential $10B+ U.S. market opportunity in IgAN and pipeline autoimmune diseases

    Potential $10B+ U.S. market opportunity in IgAN and pipeline autoimmune diseases1 LCM for BAFF and APRIL inhibition US Prevalence1 IgAN/IgAVN Sjögren’s pMN Nephrology Non-Nephrology ~500K ~700K gMG FSGS SLE MCD ITP AAV SSc LN 1. Vera Therapeutics corporate estimates for peak year market opportunity

  27. Slide 27: TRUTAKNA projected catalysts

    TRUTAKNA projected catalysts Catalyst 2026 2027 2028 US launch IgAN Phase 3 final efficacy analysis Projected full approval1 IgAN Clinical results IgAN, pMN, Clinical results FSGS, MCD Vera holds worldwide, exclusive rights to develop and commercialize TRUTAKNA 1. Subject to U.S. FDA review of full

  28. Slide 28: © 2026 Vera Therapeutics, Inc. Corporate Presentation

    © 2026 Vera Therapeutics, Inc. Corporate Presentation

Vera Therapeutics — Investor Presentation (October 2026) on 6ix